This playbook explores the challenging CGT reimbursement landscape and solutions for all stakeholders that can facilitate the patient journey.
The evolving cell and gene therapy (CGT) market includes complexities in payer approval and reimbursement across the industry landscape. A patient’s treatment journey is supported by many clinical stakeholders, each playing a role in the patient’s ability to access CGT: the referring physician, administering physician and pharmacist. Each of these stakeholders have unique perspectives, challenges and opportunities with the therapy approval and reimbursement process.
This playbook explores the many challenges in this rapidly shifting treatment and reimbursement landscape and considers potential solutions that could support a more cohesive and collaborative process from all perspectives. Highlights include:
- Stakeholder concerns, predictions and ideal solutions as pipeline forecasts indicate an increase in advanced therapies such as CGTs over the next few years.
- How single case agreements worsen administrative burden, and how different strategies can reduce that burden.
- Three trends that could help mitigate reimbursement uncertainty and address stakeholders’ concerns.
Offered Free by: BioPharma Dive’s Studio by Informa TechTarget and Cardinal Health
See All Resources from: BioPharma Dive’s Studio by Informa TechTarget and Cardinal Health
